PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expression landscape...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JCI insight Jg. 4; H. 6
Hauptverfasser:	Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States American Society for Clinical Investigation 21.03.2019
Schlagworte:	Clinical Medicine Genetics Immunology Immunotherapy Cancer
ISSN:	2379-3708, 2379-3708
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!